Glaucoma
Glaucoma
复制标题
DOI：
10.1016/s0140-6736(10)61423-7
复制
发表时间：
2011-04-16
期刊：
影响因子：
168.9
通讯作者：
Quigley, Harry A.
中科院分区：
文献类型：
--
作者：
Quigley, Harry A.
大多数医生经常接触患有两种形式青光眼之一的成年人：开角型青光眼或闭角型青光眼。基于人口的调查数据表明，每40名40岁以上的成年人中就有一人患有青光眼并丧失视觉功能，这相当于全世界有6000万人受到影响，840万人双眼失明。即使在发达国家，也有一半的青光眼病例未被诊断出来。青光眼大多数是无症状的，直到疾病晚期出现视力问题。青光眼导致的视力丧失无法恢复，因此需要改进青光眼的病例检测方法。青光眼通常用每日滴眼液药物治疗，但治疗的依从性往往不令人满意。青光眼是一种无症状的慢性疾病，其治疗挑战与慢性全身性疾病相似。与常见CNS疾病的发病机制相似意味着可能存在共同的神经保护策略。成功的基因治疗，已用于其他眼科疾病可能是可能的治疗青光眼的未来。
Most medical practitioners have regular contact with adults who have one of the two forms of glaucoma: open-angle glaucoma or angle-closure glaucoma. Data from population-based surveys indicate that one in 40 adults older than 40 years has glaucoma with loss of visual function, which equates to 60 million people worldwide being affected and 8.4 million being bilaterally blind. Even in developed countries, half of glaucoma cases are undiagnosed. Glaucoma is mostly asymptomatic until late in the disease when visual problems arise. Vision loss from glaucoma cannot be recovered, and improved case-detection methods for glaucoma are needed. Glaucoma is commonly treated with daily eye-drop drugs, but adherence to treatment is often unsatisfactory. As a usually asymptomatic and chronic disease, glaucoma has similar treatment challenges to chronic systemic diseases. Similarities to the pathogenesis of common CNS diseases mean that common neuroprotective strategies might exist. Successful gene therapy, which has been used for other eye diseases might be possible for the treatment of glaucoma in the future.